09:47 AM EST - Aralez Pharmaceuticals Inc. : Announced that the U.S. Food and Drug Administration ("FDA") has acknowledged acceptance of the New Drug Application for its investigational candidate, YOSPRALA™ for the secondary prevention of cardiovascular disease in patients at risk for aspirin-induced gastric ulcers. The FDA Prescription Drug User Fee Act goal date for a decision is September 14. Aralez Pharmaceuticals Inc.
shares T.ARZ are trading up $0.45 at $5.16.
